Table 1.
Summary of patient, tumor, and treatment characteristics
| Characteristic | n | Number |
|---|---|---|
| Sex | 343 | |
| Male (%) | 173 (50) | |
| Female (%) | 170 (50) | |
| Age, median (range) | 51 (8 months–94 years) | |
| Size (cm), median (range) | 4.0 (0.4–18.0) | |
| Anatomic site | ||
| Oral cavity (%) | 106 (31) | |
| Sinonasal (%) | 56 (16) | |
| Neck (%) | 41 (12) | |
| Thyroid (%) | 39 (11) | |
| Parotid (%) | 29 (8) | |
| Scalp (%) | 23 (7) | |
| Larynx (%) | 15 (4) | |
| Symptoms | 237 | |
| Mass/swelling | 147 (62) | |
| Nasal obstruction | 40 (17) | |
| Dysphonia | 12 (5) | |
| Incidental | 6 (3) | |
| Symptom duration (months), median (range) | 8.0 (1–180) | |
| Pain | 38 (16) | |
| Invasion | 285 | 37 (13) |
| Bone (%) | 29 (10) | |
| Vasculature (%) | 5 (2) | |
| Perineural (%) | 3 (1) | |
| Adjuvant therapy (%) | 343 | 24 (7) |
| Radiation (%) | 14 (4) | |
| Pre-operative embolization (%) | 5 (1.5) | |
| Surgical margins | 284 | |
| Positive (%) | 18 (6) | |
| CD34 positive (%) | 343 | 335 (98) |
| Bcl-2 positive (%) | 175 | 160 (91) |
| Vimentin positive (%) | 173 | 169 (98) |
| CD99 positive (%) | 122 | 92 (75) |
| S-100 positive (%) | 242 | 5 (2) |
| SMA positive (%) | 185 | 12 (6) |
| CK positive (%) | 192 | 0 (0) |
| Mitoses (hpf), median (range) | 209 | 1 (0–85) |
| ≥ 4 hpf (%) | 38 (18) | |
| Aberrant histological features (%) | 343 | 39 (11) |
| Follow up (months), median (range) | 267 | 24 (1–160) |
| Recurrence (%) | 267 | 15 (6) |
hpf high powered field